1. Adzhubei I., Jordan D. M. and Sunyaev S. R. 2013 Predicting functional effect of human missense mutations using PolyPhen-2. Curr. Protoc. Hum. Genet. 76, 7–20.
2. Anastas J. N. and Moon R. T. 2013 WNT signalling pathways as therapeutic targets in cancer. Nat. Rev. Cancer 13, 11–26.
3. Bahl C., Sharma S., Singh N. and Behera D. 2017 Single nucleotide variations in the Wnt antagonist sFRP3 (rs7775 & rs288326) and sFRP4 (rs1802073 & 1802074) genes and their association with lung cancer risk in North Indians. Meta Gene 13, 159–168.
4. Banerjee S. and Kaviani A. 2016 Worldwide prostate cancer epidemiology: differences between regions, races, and awareness programs. Int. J. Clin. Exp. Med. 2, 1–6.
5. Drake J., Shearwood A. M., White J., Friis R., Zeps N., Charles A. and Dharmarajan A. 2009 Expression of secreted frizzled-related protein 4 (SFRP4) in primary serous ovarian tumours. Eur. J. Gynaecol. Oncol. 30, 133–141.